California is first US state to ban pay-for-delay dealsCalifornia has become the first US state to ban the pharma industry practice of paying rivals to keep Share XCalifornia is first US state to ban pay-for-delay dealshttps://pharmaphorum.com/news/california-is-first-us-state-to-ban-pay-for-delay-deals/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
Mind-controlled exoskeleton suit allows paralysed man to walkResearchers in France say a man has been able to control all four of his limbs using a Share XMind-controlled exoskeleton suit allows paralysed man to walkhttps://pharmaphorum.com/news/mind-controlled-exoskeleton-suit-allows-paralysed-man-to-walk/
J&J settles Ohio lawsuits for $20m as opioid litigation train rumbles onJohnson & Johnson has managed to put opioid litigation in Ohio behind it with a $20 million settlement, Share XJ&J settles Ohio lawsuits for $20m as opioid litigation train rumbles onhttps://pharmaphorum.com/news/jj-settles-ohio-lawsuits-for-20m-as-opioid-litigation-train-rumbles-on/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
Labour government would use compulsory licensing for expensive drugsA Labour government would force pharma companies to make essential drugs available that are affordable by the NHS, Share XLabour government would use compulsory licensing for expensive drugshttps://pharmaphorum.com/news/labour-government-would-use-compulsory-licensing-for-expensive-drugs/
eLucid gets US patents for smart pill dispenser deviceHealth tech firm eLucid mHealth has been granted a pair of US patents for its recently-launched Pill Connect, Share XeLucid gets US patents for smart pill dispenser devicehttps://pharmaphorum.com/news/elucid-gets-us-patent-for-smart-pill-dispenser-device/
England is risking its own opioid epidemic, says PHEHundreds of thousands of people in England are at risk of dependency on prescription medicines like opioid painkillers, Share XEngland is risking its own opioid epidemic, says PHEhttps://pharmaphorum.com/news/england-is-risking-its-own-opioid-epidemic-says-phe/
Purdue preps bankruptcy as opioid settlement bid stumbles; reportPurdue Pharma is reported to be preparing to file for bankruptcy amid resistance to its $10-$12 billion offer Share XPurdue preps bankruptcy as opioid settlement bid stumbles; reporthttps://pharmaphorum.com/news/purdue-preps-bankruptcy-as-opioid-settlement-bid-stumbles-report/
NICE lowers threshold for blood pressure drugs in new guidanceNew guidelines on the management of high blood pressure in the UK will see thousands more patients eligible Share XNICE lowers threshold for blood pressure drugs in new guidancehttps://pharmaphorum.com/news/nice-lowers-threshold-for-blood-pressure-drugs-in-new-guidance/
J&J hit by $572m verdict in Oklahoma opioid caseJohnson & Johnson has been ordered to pay $572 million to remedy its part in the opioid crisis Share XJ&J hit by $572m verdict in Oklahoma opioid casehttps://pharmaphorum.com/news/jj-hit-by-572m-verdict-in-oklahoma-opioid-case/
Low-cost polypill could dramatically cut heart attacks, strokesA single tablet that contains four generically-available drugs – or ‘polypill’ – could offer an effective, low-cost way Share XLow-cost polypill could dramatically cut heart attacks, strokeshttps://pharmaphorum.com/news/low-cost-polypill-could-dramatically-cut-heart-attacks-strokes/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
Republican revolt threatens Senate drug pricing billA bipartisan bill voted through by the Senate Finance Committee last week is under threat from a group Share XRepublican revolt threatens Senate drug pricing billhttps://pharmaphorum.com/news/republican-revolt-threatens-senate-drug-pricing-bill/
Allergan pulls breast implants after link to rare cancerAllergan has followed through on an FDA request to carry out a worldwide recall of textured breast implant Share XAllergan pulls breast implants after link to rare cancerhttps://pharmaphorum.com/news/allergan-pulls-breast-implants-after-link-to-rare-cancer/
Vertex presses go on its cystic fibrosis triple filingVertex has launched the next phase of its plan for the cystic fibrosis market, filing for approval of Share XVertex presses go on its cystic fibrosis triple filinghttps://pharmaphorum.com/news/vertex-presses-go-on-its-cystic-fibrosis-triple-filing/
Celgene gets new approval for soon-to-be-shed OtezlaCelgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial Share XCelgene gets new approval for soon-to-be-shed Otezlahttps://pharmaphorum.com/news/celgene-gets-new-approval-for-soon-to-be-shed-otezla/
